Summary

Global Lyme Disease Market Definition and Scope
The global Lyme disease market valued at USD 3.10 billion in 2025 is anticipated to reach USD 8.00 billion by 2036, growing at 9.0% CAGR during the forecast period. Lyme disease has emerged as an important challenge for vector borne infectious disease control in North America, Europe and parts of Asia Pacific. Increasing tick populations, changing climatic conditions, higher human contact with forested ecosystems, and increasing disease surveillance activities are transforming market dynamics. Healthcare systems have accelerated the efforts to enable early diagnosis and prompt treatment to reduce long term neurological, cardiac and musculoskeletal sequelae. Diagnostic technologies have undergone significant evolution in the past decade. Conventional serological testing continues to be the clinical standard, and molecular diagnostic platforms are gaining ground in specialized healthcare settings.
Global Lyme Disease Market: Key Highlights
• The Global Lyme Disease Market was valued at USD 3.10 billion in 2025, primarily driven by increasing incidence of tick-borne infections and expanding diagnostic screening efforts.
• The market is projected to reach USD 8.00 billion by 2036, growing at a CAGR of 9.0% during 2026–2036, propelled by advancements in rapid diagnostic technologies and vaccine development.
• North America leads the global market, supported by high disease prevalence, advanced healthcare infrastructure, and established infectious disease surveillance programs.
• Asia Pacific is the fastest-growing regional market, propelled by improving diagnostic capabilities and increasing healthcare investments for infectious disease management.
• Early Localized Lyme dominates the disease stage segment because of greater diagnosis rates and timely clinical intervention before disease progression.
• Serological Tests lead the diagnosis segment owing to their widespread clinical adoption, standardized testing protocols, and reliable antibody detection capabilities.
• Antibiotic Therapy dominates the treatment segment because of its proven clinical effectiveness in eliminating bacterial infection and preventing long-term disease complications.

Research Scope and Methodology
The report analyzes the global Lyme disease market by disease stage, diagnostic modality, treatment modality, route of administration, and end user. It provides a comprehensive review of diagnostic technologies, therapeutic products, laboratory services, healthcare delivery frameworks, regulatory developments, reimbursement trends, and investment activity. Key ecosystem players include diagnostic manufacturers, pharmaceutical companies, contract research organizations, hospitals, specialty clinics, academic institutions, government agencies, and public health organizations involved in Lyme disease management.
The research methodology employs a combination of primary interviews, secondary intelligence gathering, epidemiological assessment, healthcare expenditure analysis, and competitive benchmarking. Analysts evaluate historical market performance, disease prevalence patterns, healthcare infrastructure readiness, reimbursement structures, and regulatory frameworks that influence market development. Primary research involves discussions with infectious disease specialists, laboratory directors, diagnostic technology providers, pharmaceutical executives, hospital administrators, and healthcare policymakers. Secondary research includes company annual reports, regulatory publications, government healthcare databases, peer-reviewed journals, scientific literature, and public health surveillance reports. Market estimates consider demand-side assessment across healthcare providers and patient populations, along with supply-side evaluation of diagnostic manufacturers and treatment providers. Forecast models integrate epidemiological trends, technological innovation, healthcare investment patterns, treatment adoption rates, and policy developments. Data triangulation techniques validate findings across multiple information sources to ensure analytical rigor and forecast reliability over the study period.
Key Market Segments
By Disease Stage:
Early Localized Lyme
Early Disseminated Lyme
Late Disseminated Lyme
By Diagnosis Type:
Serological Tests
Molecular Diagnostics (PCR)
Culture Tests
Others
By Treatment Type:
Antibiotic Therapy
Supportive Care
Combination Therapy
By Route of Administration:
Oral
Injectable
By End User:
Hospitals
Specialty Clinics
Diagnostic Laboratories
Research Institutes

Key Market Players
Valneva SE
Pfizer Inc.
Sanofi
Merck & Co., Inc.
GSK plc
Novartis AG
Boehringer Ingelheim
Zoetis Inc.
Bavarian Nordic
Inovio Pharmaceuticals
Industry Trends
• Industrial automation is changing the competitive landscape for laser welding machines. Digitally controlled laser systems are replacing conventional welding processes as manufacturers look to improve throughput, consistency and production flexibility. Demand is moving beyond large enterprises to include medium sized manufacturing operations.
• Fiber laser technology has emerged as the preferred platform for a number of industries, with improvements in energy efficiency, beam quality and maintenance needs driving commercial adoption. Equipment vendors are increasingly focusing on fiber laser innovation, driven by attractive economics and wide application suitability.
• Electric vehicle production is a game-changing demand driver. Battery pack production requires extremely precise welding processes that can accommodate sensitive materials and complex geometries. With global vehicle electrification gathering pace, investments in battery manufacturing are boosting laser welding adoption.
• The semiconductor industry also shapes market trends. Advanced packaging technologies require precision joining solutions that can work within tight tolerances. The trends of miniaturization continue to drive the need for high accuracy laser welding equipment.
• The integration of artificial intelligence is gaining more prominence. Machine learning algorithms now help to predict weld quality, identify defects, optimize processes and enable predictive maintenance. These capabilities reduce operational risks and improve production efficiency.
• More and more manufacturers are integrating laser welding systems with robotics platforms. Automated welding cells offer increased repeatability and enable continuous production operations. The use of collaborative robotics also opens up opportunities for flexible manufacturing environments.
• Sustainability considerations are impacting purchasing decisions. Laser welding processes generally reduce material waste and energy consumption when compared to traditional joining methods. Industrial customers are increasingly looking at environmental performance as a productivity metric.
• Medical device manufacturing is another major trend. Increasing demand for implantable devices, surgical instruments and precision healthcare components drives investment in advanced welding technologies. Regulatory requirements benefit highly controlled manufacturing processes with traceable quality outcomes.
• Regional supply chain diversification continues to influence capital expenditure patterns. Companies are increasingly establishing localized manufacturing facilities to improve resilience and reduce operational disruptions. These investments create additional opportunities for laser welding equipment suppliers.
• Digital manufacturing initiatives remain a key theme in the evolution of the market. Industrial operators are increasingly linking welding systems with enterprise software platforms, production monitoring tools and quality management systems. Data driven manufacturing environments enable greater process transparency and operational control.
• Aerospace manufacturers are increasingly adopting advanced laser welding technologies. The need for lightweight structures, high-performance materials and production precision suits well the potential of laser-based manufacturing. Defense modernization programs are also driving investment in equipment.
• Technology convergence is expected to accelerate in the future. AI, robotics, machine vision, digital twins and laser welding systems are operating more and more within integrated production ecosystems. Companies that can offer comprehensive solutions, not only standalone equipment, are expected to gain significant competitive advantages over the forecast period.
Market Determinants
• Rising Lyme Disease Incidence: Growing disease incidence directly expands demand for diagnostic services, treatment interventions, and surveillance infrastructure. Expanding tick habitats continue increasing patient volumes across endemic regions, creating sustained commercial opportunities throughout the healthcare value chain.
• Expansion of Diagnostic Testing Infrastructure: Healthcare systems increasingly invest in laboratory modernization and infectious disease testing capabilities. Enhanced diagnostic accessibility improves disease detection rates, generating higher utilization across diagnostic product categories.
• Government Surveillance Programs: National public health agencies continue strengthening disease reporting requirements and surveillance initiatives. These programs improve epidemiological visibility, increase testing volumes, and support long term market development.
• Advancements in Molecular Diagnostics: PCR based technologies improve pathogen detection capabilities in specific clinical scenarios. Technology innovation supports premium pricing opportunities while expanding diagnostic accuracy and clinical confidence.
• Treatment Accessibility Challenges: Delayed diagnosis remains a significant market constraint. Symptom overlap with other infectious and autoimmune conditions complicates clinical decision making and may reduce treatment effectiveness.
• Reimbursement and Cost Pressures: Healthcare providers face increasing pressure to balance diagnostic accuracy with cost containment objectives. Reimbursement limitations may slow adoption of advanced testing technologies in certain healthcare systems.
Opportunity Mapping Based on Market Trends
• Advanced Molecular Testing Expansion: Investment opportunities exist in next generation molecular diagnostics, multiplex testing platforms, and point of care infectious disease detection technologies capable of improving early diagnosis accuracy.
• Vaccine Development Programs: Growing disease burden supports commercial opportunities for preventive vaccine development. Successful vaccine commercialization could reshape long term market economics.
• Digital Disease Surveillance Platforms: Healthcare systems increasingly require integrated surveillance solutions. Companies offering data analytics, predictive epidemiology, and digital monitoring capabilities may capture emerging value pools.
• Emerging Geographic Markets: Rising disease awareness across Asia Pacific and selected Latin American countries creates opportunities for diagnostic manufacturers, healthcare providers, and pharmaceutical companies seeking regional expansion.
Value-Creating Segments and Growth Pockets
Early localized Lyme disease leads the market through early diagnosis awareness and timely treatment adoption.
The market is segmented by disease stage into Early Localized Lyme, Early Disseminated Lyme, and Late Disseminated Lyme. Currently, Early Localized Lyme holds the leading market position with an estimated 56.4% share in 2025. The leadership position can be attributed to increasing disease awareness, high physician familiarity with early symptoms, high rates of diagnostic testing, high success rates in treatment, and public health emphasis on early intervention. Healthcare systems focus on early disease management as timely treatment reduces long term complications and lowers the overall healthcare cost. Late Disseminated Lyme is expected to grow at the highest CAGR of 15.8% during the period 2026-2036. Future growth can be attributed to improved diagnosis of complex cases, more referrals to specialty centers, increased research focus, improved patient monitoring programs, and increased awareness of longterm disease effects.
Serological tests dominate Lyme disease diagnostics through established clinical guidelines and broad laboratory accessibility.
The market is segmented based on Diagnosis Type into Serological Tests, Molecular Diagnostics (PCR), Culture Tests, and Others. Serological Tests are leading the market with an estimated share of 61.7% in 2025. The leading position is supported by well-established clinical guidelines, widespread availability in laboratories, reimbursement support, cost-effectiveness, and extensive physicians’ familiarity.
Molecular Diagnostics (PCR) is expected to witness the highest CAGR of 18.6% during the forecast period of 2026 to 2036. PCR technologies are increasingly favored by investment trends due to improved specificity, technological advancement, laboratory automation trends, growing clinical evidence, and increasing demand for rapid pathogen detection.
Antibiotic therapy leads Lyme disease treatment through proven clinical efficacy and guideline-based standard of care.
By treatment type, the market is segmented into Antibiotic Therapy, Supportive Care and Combination Therapy. Antibiotic Therapy is the largest segment by 2025 with an estimated 67.3% market share. Commercial use is strongest for antibiotic therapy, driven by guideline recommendations, demonstrated efficacy, wide acceptance among physicians, established reimbursement structures and widespread product availability. Combination Therapy is expected to record the highest CAGR of 16.9% during 2026-2036. Future growth is driven by increased management of complex disease cases, multidisciplinary treatment strategies, increased clinical research and greater focus on comprehensive patient outcomes.
Oral therapies dominate treatment delivery through patient convenience and widespread outpatient use.
By Route of Administration, the market is segmented into Oral and Injectable. Oral administration dominates the market with an estimated share of 64.8% in 2025. The dominance is attributed to patient convenience, lower treatment costs, outpatient setting suitability, high compliance levels, and established prescribing practices. Injectable administration is projected to register the fastest CAGR of 14.7% over the forecast period of 2026-2036. The acceleration in growth is supported by increasing treatment of severe disease presentations, hospitalbased management protocols, and demand for higher intensity therapeutic interventions.
Hospitals lead Lyme disease management through integrated diagnostics and multidisciplinary infectious disease care.
By End User, the market is segmented into Hospitals, Specialty Clinics, Diagnostic Laboratories, and Research Institutes. Hospitals accounted for the largest market share of 48.6% in 2025 and are expected to maintain dominance during the forecast period, owing to the integrated diagnostic capabilities, multidisciplinary treatment infrastructure, higher patient inflow, reimbursement coverage and advanced infectious disease expertise.
Diagnostic Laboratories are expected to grow with the fastest CAGR of 17.4% during 2026-2036, driven by the increasing testing volumes, investments in laboratory automation, growing adoption of molecular diagnostic tests and rising outsourcing of specialized testing services.
Regional Market Assessment
North America leads the Lyme disease market through high disease prevalence and advanced diagnostic infrastructure.
The North America dominates the global Lyme disease market and is projected to hold 43.5% share by 2025. The regional dominance is attributed to high incidence of disease, well-developed healthcare infrastructure, strong surveillance systems for infectious diseases and high penetration of diagnostic tests. According to the reports of United States Centers for Disease Control and Prevention in 2024, Lyme disease continues to be a major vector borne disease concern in several states. The region is supported by high level of awareness among physicians, favorable reimbursement policies, established laboratory networks and strong presence of pharmaceutical companies. Research institutes are actively involved in conducting clinical studies related to diagnostics, therapeutics and vaccine development. Government agencies still support surveillance programs and public education campaigns. Heavy investments in molecular diagnostics and digital health technologies also add further to the market maturity. Commercial opportunities remain focused in advanced testing solutions and integrated disease management services.
Europe strengthens Lyme disease management through robust surveillance systems and established public healthcare networks.
Europe remains a key Lyme disease market, with wide disease surveillance, robust healthcare access and engaged public health. Several countries have robust reporting structures for tick borne diseases. Healthcare providers are increasingly focused on early diagnosis and treatment intervention. Diagnostic laboratory networks continue to expand in advanced testing capabilities, while academic institutions support ongoing research efforts. Regulatory agencies maintain high quality standards for diagnostic products and clinical management protocols. Improved awareness among healthcare providers leads to higher rates of diagnosis in endemic areas. Pharmaceutical companies continue to assess novel therapeutic approaches and prophylactic options. The region is also aided by collaborative research projects that improve the understanding of disease epidemiology and management strategies. Long-term market growth is supported by healthcare modernization initiatives and ongoing investment in infectious disease preparedness.
Asia Pacific emerges as the fastest-growing Lyme disease market through expanding healthcare infrastructure and diagnostic capabilities.
The Asia Pacific region is expected to register the highest CAGR of 16.8% from 2026 to 2036. The growth momentum is driven by the expansion of healthcare infrastructure, increasing awareness about diseases, the enhancement of diagnostic capabilities, and the improvement of infectious disease surveillance programs. Governments across the region are actively investing in the modernization of healthcare systems and the expansion of laboratory capacities. The huge population base provides significant opportunities for diagnostic manufacturers and healthcare providers. Furthermore, research institutions are increasingly engaging in studies pertaining to vector-borne diseases, which is helping to increase scientific knowledge and diagnostic readiness. Private sector investment in healthcare also encourages technology adoption. Increased availability of molecular diagnostics and infectious disease expertise broadens market access. Public-private-partnerships and technology transfer programs offer additional impetus. Market opportunities remain especially promising in emerging healthcare economies where diagnostic availability is increasing.
LAMEA expands Lyme disease market opportunities through healthcare modernization and enhanced infectious disease surveillance.
The LAMEA region is seeing potential for emerging growth due to healthcare infrastructure development, improved disease surveillance systems, and increasing public health investment. Latin American countries are increasingly enhancing infectious disease monitoring capabilities. Middle Eastern healthcare systems are continuing to invest in laboratory modernization and specialized diagnostic services. African markets are benefiting from gradual improvements in healthcare accessibility and disease awareness programs. Government agencies and international health organizations are supporting surveillance initiatives aimed at improving epidemiological understanding. Diagnostic manufacturers are increasingly looking to grow regionally to access unmet demand Healthcare modernization programs are enabling greater access to laboratory testing and clinical care services The market is less mature than North America and Europe, but the long-term growth outlook is positive with continued healthcare investment and strengthening public health infrastructure
Recent Developments
• March 2025: Pfizer announced continued advancement of its Lyme disease vaccine collaboration with Valneva through ongoing clinical development activities. The initiative strengthens preventive healthcare capabilities and reflects growing industry interest in disease prevention strategies.
• October 2024: Valneva reported progress in latestage clinical evaluation of its Lyme disease vaccine candidate. The development supports commercialization prospects within preventive infectious disease management.
• July 2024: Quest Diagnostics expanded infectious disease testing capabilities across selected laboratory networks. The investment strengthens diagnostic accessibility and reflects increasing demand for specialized testing services.
• May 2024: Labcorp enhanced molecular diagnostic service offerings for infectious disease applications. The expansion supports faster disease detection capabilities and aligns with broader laboratory modernization trends.
Critical Business Questions Addressed
How large is the global Lyme disease market opportunity through 2036?
The report evaluates market expansion potential across diagnostics, therapeutics, and healthcare services while identifying primary value creation drivers.
Which segments generate the strongest commercial returns?
The analysis identifies dominant revenue contributors and emerging high growth segments across diagnosis, treatment, and healthcare delivery categories.
What factors will shape competitive positioning over the next decade?
The report assesses technology innovation, regulatory developments, clinical adoption trends, and investment priorities influencing market leadership.
Which regions offer the most attractive expansion opportunities?
The study examines regional growth patterns, healthcare infrastructure readiness, disease prevalence trends, and investment environments.
How should stakeholders prioritize future investments?
The report highlights strategic opportunities across molecular diagnostics, vaccine development, laboratory services, and digital disease management platforms.
Beyond the Forecast
• The Lyme disease market increasingly reflects the convergence of infectious disease surveillance, molecular diagnostics, and precision healthcare delivery.
• Competitive advantage will depend less on product availability and more on diagnostic accuracy, clinical integration, and ecosystem partnerships.
• Organizations that align innovation pipelines with preventive healthcare strategies, advanced testing technologies, and expanding surveillance networks will capture the strongest long term value creation opportunities.

ページTOPに戻る

Table of Contents

Table of Contents
Chapter 1. Global Lyme disease Market Report Scope & Methodology
1.1. Market Definition
1.2. Market Segmentation
1.3. Research Assumption
1.3.1. Inclusion & Exclusion
1.3.2. Limitations
1.4. Research Objective
1.5. Research Methodology
1.5.1. Forecast Model
1.5.2. Desk Research
1.5.3. Top Down and Bottom-Up Approach
1.6. Research Attributes
1.7. Years Considered for the Study
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Strategic Insights
2.3. Top Findings
2.4. CEO/CXO Standpoint
2.5. ESG Analysis
Chapter 3. Global Lyme disease Market Forces Analysis
3.1. Market Forces Shaping The Global Lyme disease Market (2025-2036)
3.2. Drivers
3.2.1. Rising Incidence of Lyme Disease Worldwide
3.2.2. Growing Awareness and Early Diagnosis Initiatives
3.2.3. Advancements in Diagnostic Technologies
3.2.4. Increased Investment in Vaccine and Therapeutic Development
3.3. Restraints
3.3.1. Diagnostic Challenges and Misdiagnosis
3.3.2. Limited Availability of Approved Vaccines
3.4. Opportunities
3.4.1. Development and Commercialization of Lyme Disease Vaccines
3.4.2. Expansion of Advanced Molecular and Point-of-Care Diagnostics

Chapter 4. Global Lyme disease Industry Analysis
4.1. Porter’s 5 Forces Model
4.2. Porter’s 5 Force Forecast Model (2025-2036)
4.3. PESTEL Analysis
4.4. Macroeconomic Industry Trends
4.4.1. Parent Market Trends
4.4.2. GDP Trends & Forecasts
4.5. Value Chain Analysis
4.6. Top Investment Trends & Forecasts
4.7. Top Winning Strategies (2025)
4.8. Market Share Analysis (2025)
4.9. Pricing Analysis
4.10. Investment & Funding Scenario
4.11. Impact of Geopolitical & Trade Policy Volatility on the Market

Chapter 5. AI Adoption Trends and Market Influence
5.1. AI Readiness Index
5.2. Key Emerging Technologies
5.3. Patent Analysis
5.4. Top Case Studies

Chapter 6. Global Lyme disease Market Size & Forecasts by Disease Stage 2025-2036
6.1. Market Overview
6.2. Global Lyme disease Market Performance - Potential Analysis (2025)
6.3. Early Localized Lyme
6.3.1. Top Countries Breakdown Estimates & Forecasts, 2025-2036
6.3.2. Market size analysis, by region, 2025-2036
6.4. Early Disseminated Lyme
6.4.1. Top Countries Breakdown Estimates & Forecasts, 2025-2036
6.4.2. Market size analysis, by region, 2025-2036
6.5. Late Disseminated Lyme
6.5.1. Top Countries Breakdown Estimates & Forecasts, 2025-2036
6.5.2. Market size analysis, by region, 2025-2036

Chapter 7. Global Lyme disease Market Size & Forecasts by Diagnosis Type 2025-2036
7.1. Market Overview
7.2. Global Lyme disease Market Performance - Potential Analysis (2025)
7.3. Serological Tests
7.3.1. Top Countries Breakdown Estimates & Forecasts, 2025-2036
7.3.2. Market size analysis, by region, 2025-2036
7.4. Molecular Diagnostics (PCR)
7.4.1. Top Countries Breakdown Estimates & Forecasts, 2025-2036
7.4.2. Market size analysis, by region, 2025-2036
7.5. Culture Tests
7.5.1. Top Countries Breakdown Estimates & Forecasts, 2025-2036
7.5.2. Market size analysis, by region, 2025-2036
7.6. Others
7.6.1. Top Countries Breakdown Estimates & Forecasts, 2025-2036
7.6.2. Market size analysis, by region, 2025-2036

Chapter 8. Global Lyme disease Market Size & Forecasts by Treatment Type 2025-2036
8.1. Market Overview
8.2. Global Lyme disease Market Performance - Potential Analysis (2025)
8.3. Antibiotic Therapy
8.3.1. Top Countries Breakdown Estimates & Forecasts, 2025-2036
8.3.2. Market size analysis, by region, 2025-2036
8.4. Supportive Care
8.4.1. Top Countries Breakdown Estimates & Forecasts, 2025-2036
8.4.2. Market size analysis, by region, 2025-2036
8.5. Combination Therapy
8.5.1. Top Countries Breakdown Estimates & Forecasts, 2025-2036
8.5.2. Market size analysis, by region, 2025-2036

Chapter 9. Global Lyme disease Market Size & Forecasts by Route of Administration 2025-2036
9.1. Market Overview
9.2. Global Lyme disease Market Performance - Potential Analysis (2025)
9.3. Oral
9.3.1. Top Countries Breakdown Estimates & Forecasts, 2025-2036
9.3.2. Market size analysis, by region, 2025-2036
9.4. Injectable
9.4.1. Top Countries Breakdown Estimates & Forecasts, 2025-2036
9.4.2. Market size analysis, by region, 2025-2036

Chapter 10. Global Lyme disease Market Size & Forecasts by End User 2025-2036
10.1. Market Overview
10.2. Global Lyme disease Market Performance - Potential Analysis (2025)
10.3. Hospitals
10.3.1. Top Countries Breakdown Estimates & Forecasts, 2025-2036
10.3.2. Market size analysis, by region, 2025-2036
10.4. Specialty Clinics
10.4.1. Top Countries Breakdown Estimates & Forecasts, 2025-2036
10.4.2. Market size analysis, by region, 2025-2036
10.5. Diagnostic Laboratories
10.5.1. Top Countries Breakdown Estimates & Forecasts, 2025-2036
10.5.2. Market size analysis, by region, 2025-2036
10.6. Research Institutes
10.6.1. Top Countries Breakdown Estimates & Forecasts, 2025-2036
10.6.2. Market size analysis, by region, 2025-2036

Chapter 11. Global Lyme disease Market Size & Forecasts by Region 2025-2036
11.1. Growth Lyme disease Market, Regional Market Snapshot
11.2. Top Leading & Emerging Countries
11.3. North America Lyme disease Market
11.3.1. U.S. Lyme disease Market
11.3.1.1. Disease Stage breakdown size & forecasts, 2025-2036
11.3.1.2. Diagnosis Type breakdown size & forecasts, 2025-2036
11.3.1.3. Treatment Type breakdown size & forecasts, 2025-2036
11.3.1.4. Route of Administration breakdown size & forecasts, 2025-2036
11.3.1.5. End User breakdown size & forecasts, 2025-2036
11.3.2. Canada Lyme disease Market
11.4. Europe Lyme disease Market
11.4.1. UK Lyme disease Market
11.4.2. Germany Lyme disease Market
11.4.3. France Lyme disease Market
11.4.4. Spain Lyme disease Market
11.4.5. Italy Lyme disease Market
11.4.6. Rest of Europe Lyme disease Market
11.5. Asia Pacific Lyme disease Market
11.5.1. China Lyme disease Market
11.5.2. India Lyme disease Market
11.5.3. Japan Lyme disease Market
11.5.4. Australia Lyme disease Market
11.5.5. South Korea Lyme disease Market
11.5.6. Rest of APAC Lyme disease Market
11.6. Latin America Lyme disease Market
11.6.1. Brazil Lyme disease Market
11.6.2. Mexico Lyme disease Market
11.7. Middle East and Africa Lyme disease Market
11.7.1. UAE Lyme disease Market
11.7.2. Saudi Arabia (KSA) Lyme disease Market
11.7.3. South Africa Lyme disease Market

Chapter 12. Competitive Intelligence
12.1. Top Market Strategies
12.2. Valneva SE
12.2.1. Company Overview
12.2.2. Key Executives
12.2.3. Company Snapshot
12.2.4. Financial Performance (Subject to Data Availability)
12.2.5. Product/Services Port
12.2.6. Recent Development
12.2.7. Market Strategies
12.2.8. SWOT Analysis
12.3. Pfizer Inc.
12.4. Sanofi
12.5. Merck & Co., Inc.
12.6. GSK plc
12.7. Novartis AG
12.8. Boehringer Ingelheim
12.9. Zoetis Inc.
12.10. Bavarian Nordic
12.11. Inovio Pharmaceuticals